Genetic vulnerabilities upon inhibition of DNA damage response

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Targeting the DNA damage response (DDR) is a promising cancer therapy strategy.
• Lack of predictive biomarkers limits the efficacy of DDR-targeted cancer treatments.

Purpose of the Study:

• To identify genetic vulnerabilities influencing cellular responses to DDR inhibition using CRISPR screens.
• To discover biomarkers for predicting sensitivity to DDR-targeting agents in cancer therapy.

Main Methods:

• Conducted CRISPR screens with inhibitors targeting key DDR mediators: ATR, ATM, DNA-PK, and CHK1.
• Analyzed genetic interactions with DDR inhibition to identify determinants of drug sensitivity and resistance.

Main Results:

• YWHAE loss identified as a key determinant of sensitivity to CHK1 inhibition.
• KLHL15 loss shown to protect cells from ATM inhibition-induced DNA damage.
• APEX1 loss validated to sensitize cells to DNA-PK inhibition.
• Combination of ATM and PARP inhibitors induced significant cancer cell death, likely via apoptosis.

Conclusions:

• CRISPR screens provide a global view of genetic interactions with DDR inhibition.
• Identified specific genetic vulnerabilities that can serve as predictive biomarkers for DDR-targeted therapies.
• Findings enhance understanding of DDR pathways and support the clinical application of DDR inhibitors in cancer treatment.